Monograph Details
|
|
Neoplasms
> Hormones and antagonists
|
|
FEMARA |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Aromatase inhibitor. |
| Generic Name |
|
Letrozole 2.5mg; tabs. |
| Indications |
|
In postmenopausal women: Adjuvant treatment of hormone receptor positive early breast cancer; Extended adjuvant treatment of early breast cancer after 5 years of adjuvant tamoxifen therapy; First-line treatment of hormone receptor positive or unknown, locally advanced or metastatic breast cancer; Treatment of advanced breast cancer with disease progression following antiestrogen therapy. |
| Children |
|
Not applicable. |
| Adults |
|
2.5mg once daily. Continue until tumor progression is evident. Adjuvant or extended adjuvant therapy: treat for at least 24 months (see literature). Severe hepatic impairment or cirrhosis: 2.5mg every other day. |
| Contraindications |
|
Women of premenopausal endocrine status. |
| Precautions |
|
Severe renal or hepatic impairment. Monitor bone mineral density. Pregnancy (Cat.D): not recommended. Nursing mothers. |
| Adverse Reactions |
|
Pain (bone and other), hot flashes, GI upset, arthralgia, fatigue, dizziness, dyspnea, cough, headache, insomnia, hypertension, edema, alopecia, anorexia, weight changes, hypercalcemia, pleural effusion, sweating, vertigo; thromboembolic or cardio- or cerebrovascular events (rare). |
| How Supplied |
|
Tabs—30 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
